NASDAQ:ILMN

Illumina Competitors

$399.00
-2.96 (-0.74 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$390.52
Now: $399.00
$402.39
50-Day Range
$368.96
MA: $407.06
$446.50
52-Week Range
$260.42
Now: $399.00
$555.77
Volume1.18 million shs
Average Volume1.20 million shs
Market Capitalization$58.21 billion
P/E Ratio92.58
Dividend YieldN/A
Beta1.14

Competitors

Illumina (NASDAQ:ILMN) Vs. TMO, A, MTD, BIO, WAT, and TECH

Should you be buying ILMN stock or one of its competitors? Companies in the sub-industry of "life sciences tools & services" are considered alternatives and competitors to Illumina, including Thermo Fisher Scientific (TMO), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), Waters (WAT), and Bio-Techne (TECH).

Illumina (NASDAQ:ILMN) and Thermo Fisher Scientific (NYSE:TMO) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, institutional ownership and valuation.

Profitability

This table compares Illumina and Thermo Fisher Scientific's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Illumina19.70%15.93%10.09%
Thermo Fisher Scientific17.12%21.35%10.55%

Volatility and Risk

Illumina has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, Thermo Fisher Scientific has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500.

Earnings & Valuation

This table compares Illumina and Thermo Fisher Scientific's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Illumina$3.54 billion16.43$1.00 billion$6.5760.73
Thermo Fisher Scientific$25.54 billion7.58$3.70 billion$12.3539.91

Thermo Fisher Scientific has higher revenue and earnings than Illumina. Thermo Fisher Scientific is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

90.0% of Illumina shares are owned by institutional investors. Comparatively, 87.2% of Thermo Fisher Scientific shares are owned by institutional investors. 0.4% of Illumina shares are owned by company insiders. Comparatively, 0.4% of Thermo Fisher Scientific shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations for Illumina and Thermo Fisher Scientific, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Illumina48602.11
Thermo Fisher Scientific031802.86

Illumina currently has a consensus target price of $370.5789, indicating a potential downside of 7.12%. Thermo Fisher Scientific has a consensus target price of $527.05, indicating a potential upside of 6.92%. Given Thermo Fisher Scientific's stronger consensus rating and higher possible upside, analysts plainly believe Thermo Fisher Scientific is more favorable than Illumina.

Summary

Thermo Fisher Scientific beats Illumina on 9 of the 14 factors compared between the two stocks.

Agilent Technologies (NYSE:A) and Illumina (NASDAQ:ILMN) are both large-cap computer and technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Profitability

This table compares Agilent Technologies and Illumina's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Agilent Technologies13.47%21.02%10.73%
Illumina19.70%15.93%10.09%

Risk and Volatility

Agilent Technologies has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Illumina has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.

Valuation and Earnings

This table compares Agilent Technologies and Illumina's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agilent Technologies$5.34 billion7.68$719 million$3.2841.03
Illumina$3.54 billion16.43$1.00 billion$6.5760.73

Illumina has lower revenue, but higher earnings than Agilent Technologies. Agilent Technologies is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

90.0% of Illumina shares are owned by institutional investors. 0.4% of Illumina shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for Agilent Technologies and Illumina, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Agilent Technologies071902.73
Illumina48602.11

Agilent Technologies presently has a consensus price target of $106.1850, indicating a potential downside of 21.10%. Illumina has a consensus price target of $370.5789, indicating a potential downside of 7.12%. Given Illumina's higher possible upside, analysts clearly believe Illumina is more favorable than Agilent Technologies.

Summary

Illumina beats Agilent Technologies on 9 of the 14 factors compared between the two stocks.

Mettler-Toledo International (NYSE:MTD) and Illumina (NASDAQ:ILMN) are both large-cap computer and technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Profitability

This table compares Mettler-Toledo International and Illumina's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mettler-Toledo International19.36%144.89%21.11%
Illumina19.70%15.93%10.09%

Risk and Volatility

Mettler-Toledo International has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Illumina has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.

Valuation and Earnings

This table compares Mettler-Toledo International and Illumina's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mettler-Toledo International$3.01 billion9.94$561.11 million$22.7756.32
Illumina$3.54 billion16.43$1.00 billion$6.5760.73

Illumina has higher revenue and earnings than Mettler-Toledo International. Mettler-Toledo International is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

93.2% of Mettler-Toledo International shares are owned by institutional investors. Comparatively, 90.0% of Illumina shares are owned by institutional investors. 3.2% of Mettler-Toledo International shares are owned by insiders. Comparatively, 0.4% of Illumina shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for Mettler-Toledo International and Illumina, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mettler-Toledo International35101.78
Illumina48602.11

Mettler-Toledo International presently has a consensus price target of $971.3750, indicating a potential downside of 24.25%. Illumina has a consensus price target of $370.5789, indicating a potential downside of 7.12%. Given Illumina's stronger consensus rating and higher possible upside, analysts clearly believe Illumina is more favorable than Mettler-Toledo International.

Summary

Illumina beats Mettler-Toledo International on 9 of the 14 factors compared between the two stocks.

Bio-Rad Laboratories (NYSE:BIO) and Illumina (NASDAQ:ILMN) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Profitability

This table compares Bio-Rad Laboratories and Illumina's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bio-Rad Laboratories147.91%3.77%2.74%
Illumina19.70%15.93%10.09%

Risk and Volatility

Bio-Rad Laboratories has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Illumina has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.

Valuation and Earnings

This table compares Bio-Rad Laboratories and Illumina's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.31 billion8.08$1.76 billion$7.0688.69
Illumina$3.54 billion16.43$1.00 billion$6.5760.73

Bio-Rad Laboratories has higher earnings, but lower revenue than Illumina. Illumina is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

63.0% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 90.0% of Illumina shares are owned by institutional investors. 27.5% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 0.4% of Illumina shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for Bio-Rad Laboratories and Illumina, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bio-Rad Laboratories00303.00
Illumina48602.11

Bio-Rad Laboratories presently has a consensus price target of $700.00, indicating a potential upside of 11.80%. Illumina has a consensus price target of $370.5789, indicating a potential downside of 7.12%. Given Bio-Rad Laboratories' stronger consensus rating and higher possible upside, analysts clearly believe Bio-Rad Laboratories is more favorable than Illumina.

Summary

Illumina beats Bio-Rad Laboratories on 8 of the 14 factors compared between the two stocks.

Waters (NYSE:WAT) and Illumina (NASDAQ:ILMN) are both large-cap computer and technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Profitability

This table compares Waters and Illumina's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Waters22.61%-349.31%21.11%
Illumina19.70%15.93%10.09%

Insider & Institutional Ownership

91.8% of Waters shares are owned by institutional investors. Comparatively, 90.0% of Illumina shares are owned by institutional investors. 1.5% of Waters shares are owned by insiders. Comparatively, 0.4% of Illumina shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Waters has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, Illumina has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Waters and Illumina, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Waters48101.77
Illumina48602.11

Waters presently has a consensus price target of $224.20, indicating a potential downside of 25.24%. Illumina has a consensus price target of $370.5789, indicating a potential downside of 7.12%. Given Illumina's stronger consensus rating and higher possible upside, analysts clearly believe Illumina is more favorable than Waters.

Valuation and Earnings

This table compares Waters and Illumina's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Waters$2.41 billion7.73$592.20 million$8.9933.36
Illumina$3.54 billion16.43$1.00 billion$6.5760.73

Illumina has higher revenue and earnings than Waters. Waters is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Summary

Illumina beats Waters on 9 of the 14 factors compared between the two stocks.

Bio-Techne (NASDAQ:TECH) and Illumina (NASDAQ:ILMN) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership.

Profitability

This table compares Bio-Techne and Illumina's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bio-Techne32.69%12.20%8.09%
Illumina19.70%15.93%10.09%

Insider and Institutional Ownership

93.8% of Bio-Techne shares are owned by institutional investors. Comparatively, 90.0% of Illumina shares are owned by institutional investors. 3.8% of Bio-Techne shares are owned by company insiders. Comparatively, 0.4% of Illumina shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Bio-Techne has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, Illumina has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Bio-Techne and Illumina, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bio-Techne03702.70
Illumina48602.11

Bio-Techne currently has a consensus target price of $367.50, suggesting a potential downside of 12.20%. Illumina has a consensus target price of $370.5789, suggesting a potential downside of 7.12%. Given Illumina's higher possible upside, analysts plainly believe Illumina is more favorable than Bio-Techne.

Earnings and Valuation

This table compares Bio-Techne and Illumina's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Techne$738.69 million21.98$229.30 million$3.86108.43
Illumina$3.54 billion16.43$1.00 billion$6.5760.73

Illumina has higher revenue and earnings than Bio-Techne. Illumina is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Summary

Illumina beats Bio-Techne on 8 of the 14 factors compared between the two stocks.


Illumina Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Thermo Fisher Scientific logo
TMO
Thermo Fisher Scientific
2.1$492.92-0.3%$193.73 billion$25.54 billion40.40Analyst Report
Unusual Options Activity
News Coverage
Agilent Technologies logo
A
Agilent Technologies
1.8$134.58-1.0%$41.01 billion$5.34 billion58.51Insider Selling
High Trading Volume
News Coverage
Mettler-Toledo International logo
MTD
Mettler-Toledo International
1.3$1,282.33-1.6%$29.91 billion$3.01 billion53.95
Bio-Rad Laboratories logo
BIO
Bio-Rad Laboratories
1.5$626.12-0.2%$18.69 billion$2.31 billion5.36News Coverage
Waters logo
WAT
Waters
1.3$299.90-0.1%$18.61 billion$2.41 billion37.35
Bio-Techne logo
TECH
Bio-Techne
2.0$418.55-0.8%$16.24 billion$738.69 million66.97
Charles River Laboratories International logo
CRL
Charles River Laboratories International
1.3$323.38-0.9%$16.24 billion$2.62 billion53.90Analyst Upgrade
Insider Selling
News Coverage
PerkinElmer logo
PKI
PerkinElmer
1.9$133.16-1.1%$14.92 billion$2.88 billion36.18
Bruker logo
BRKR
Bruker
1.9$67.65-0.3%$10.25 billion$2.07 billion66.32Unusual Options Activity
Pacific Biosciences of California logo
PACB
Pacific Biosciences of California
1.6$31.53-4.2%$6.09 billion$90.89 million-112.60Analyst Upgrade
Gap Down
Luminex logo
LMNX
Luminex
1.5$36.71-0.2%$1.74 billion$334.64 million94.13Analyst Downgrade
Fluidigm logo
FLDM
Fluidigm
1.8$4.63-1.5%$345.15 million$117.24 million-6.91News Coverage
Gap Down
Harvard Bioscience logo
HBIO
Harvard Bioscience
1.8$6.97-2.7%$278.29 million$116.18 million-38.72Analyst Upgrade
News Coverage
aTyr Pharma logo
LIFE
aTyr Pharma
1.5$3.77-1.9%$60.36 million$420,000.00-1.42Increase in Short Interest
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.